;The Human Cancer Virology (VR) program is advancing understanding, prevention, and treatment of virus linked cancers and other cancers through fundamental and translational studies that encompass five of the seven well-established human tumor viruses. Program members are defining the mechanisms by which human tumor viruses replicate, maintain chronic infection, and promote tumor induction and maintenance;determining the progressive, genome-wide molecular changes in the development of virus-associated tumors;identifying viral and cellular biomarkers for improved tumor diagnosis, prognosis and treatment selection;and using their results to develop new approaches to prevent and treat tumor virus infection and oncogenesis. Program members'efforts have already changed UW-Madison clinical practices for hepatitis C virus treatment, are moving forward in testing new treatment approaches for papillomavirus-induced head/neck and cervical cancer, and have established strong foundations for similarly novel control strategies for cancers induced by Epstein-Barr virus and other viruses. To achieve their goals, program members collaborate extensively intra- and inter-programmatically, and integrate novel, synergistic approaches using cell culture, mouse models based on transgenes and patient explants, and large collections of relevant human tumor samples. The twelve program members include three practicing physician-scientists (two M.D.s and one M.D./Ph.D.) and nine Ph.D.s who collectively comprise a highly productive, interactive, diverse, and critical mass of expertise across the full spectrum of tumor virology from molecular biology to clinical studies. They represent six departments (Oncology, Medical Microbiology and Immunology, Medicine, Molecular Virology, Plant Pathology) in four Schools (School of Medicine and Public Health, Graduate School, College of Engineering, College of Agriculture and Life Sciences), plus two private biomedical research institutes (Howard Hughes Medical Institute and Morgridge Institute for Research). They have $3.8M/yr funding from NCI and $2.7M in other peer-reviewed funding. From 2007-2011 they had 133 cancer-relevant publications, which were overall 6% intra-programmatic and 15% inter-programmatic. For 2011, intra-programmatic publications advanced to 12% and inter-programmatic publications to 25%. This increase in collaborative publications reflects a steadily increasing number of joint projects and grants within and beyond the program.
;Specific human tumor viruses have been causally associated with at least 15-20% of all human cancers. The Human Cancer Virology program advances the understanding, prevention, and treatment of virus-linked cancers.
|Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70|
|Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24|
|Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31|
|Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17|
|Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607|
|Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609|
|Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8|
|LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76|
|Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9|
|Nihal, Minakshi; Ahmad, Nihal; Wood, Gary S (2014) SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 13:632-40|
Showing the most recent 10 out of 472 publications